University of Sussex
Browse
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine experience from.pdf (1.72 MB)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

Download (1.72 MB)
journal contribution
posted on 2023-06-10, 01:39 authored by Farhad Ravandi, Gail J Roboz, Andrew H Wei, Hartmut Döhner, Christopher Pocock, Dominik Selleslag, Pau Montesinos, Hamid Sayar, Maurizio Musso, Angela Figuera-Alvarez, Hana Safah, William Tse, Sang Kyun Sohn, Devendra Hiwase, Timothy ChevassutTimothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, Rochelle Bailey, Jianhua Zhong, C L Beach, Herve Dombret
Background Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall survival by 9.9 months (P?

History

Publication status

  • Published

File Version

  • Published version

Journal

Journal of Hematology and Oncology

ISSN

1756-8722

Publisher

BMC

Issue

1

Volume

14

Page range

1-14

Article number

a133

Event location

England

Department affiliated with

  • Clinical and Experimental Medicine Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2021-11-08

First Open Access (FOA) Date

2021-11-08

First Compliant Deposit (FCD) Date

2021-11-05

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC